rhPDGF-BB vs EGF
Head-to-head comparison of rhPDGF-BB (Recombinant Human Platelet-Derived Growth Factor-BB) and EGF (Human Epidermal Growth Factor) — benefits, dosing, side effects, research data, and where to buy.
| Property | rhPDGF-BB | EGF |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Recombinant Human Platelet-Derived Growth Factor-BB | Human Epidermal Growth Factor |
| Molecular Weight | 24.8 kDa | 6.0 kDa |
| Half-Life | minutes | minutes |
| Amino Acids | 109 per chain (homodimer) | 53 |
| Typical Dose | 100 µg/g gel once daily | 0.04–0.1 mg/cm²/day |
| Route | Topical | Topical |
| Purity | ≥98% | ≥98% |
| Studies Count | 400 | 650 |
| Research Status | Clinical | Clinical |
rhPDGF-BB Benefits
- ✓cell migration
- ✓fibroblast proliferation
- ✓collagen deposition
- ✓diabetic ulcer healing
EGF Benefits
- ✓re-epithelialization
- ✓fibroblast activation
- ✓angiogenesis support
- ✓faster ulcer closure
rhPDGF-BB Dosing
Topical once daily|apply to clean wound bed|continue until complete granulation/closure
EGF Dosing
Topical daily|0.04–0.1 mg/cm²|short courses until granulation/closure
rhPDGF-BB Side Effects
- ⚠local erythema
- ⚠pain
- ⚠edema
- ⚠theoretical tumor-promoting risk
EGF Side Effects
- ⚠local irritation
- ⚠erythema
- ⚠theoretical hyperproliferation
- ⚠pain at site
Research Overview
rhPDGF-BB
rhPDGF-BB has one of the strongest clinical wound-healing datasets among growth factors and is best known for chronic diabetic foot ulcers. Its efficacy is tied to chemotaxis and mitogenesis in fibroblasts, smooth muscle cells, and macrophage-lineage cells.
EGF
Human and animal studies show EGF can accelerate epithelial migration and wound closure, especially in burns, ulcers, and mucosal injury. Its best evidence is for topical or local delivery because systemic exposure is brief and the effect is highly localized.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.